<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05111769</url>
  </required_header>
  <id_info>
    <org_study_id>SEPSIS-HF</org_study_id>
    <nct_id>NCT05111769</nct_id>
  </id_info>
  <brief_title>Preliminary Study on the Clinical Effect of Recombinant Human Brain Natriuretic Peptide on Sepsis Complicated With Heart Failure</brief_title>
  <official_title>Preliminary Study on the Clinical Effect of Recombinant Human Brain Natriuretic Peptide on Sepsis Complicated With Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators intend to conduct clinical studies to determine the efficacy of rhBNP in&#xD;
      the treatment of septic related dysfunction and kidney dysfunction&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sepsis is one of the common critical diseases in ICU with high mortality. Septic shock&#xD;
      patients are often accompanied by multiple organ dysfunction (MODS), of which more than 50%&#xD;
      of patients with varying degrees of myocardial injury.The investigators hope to find a drug&#xD;
      with a protective effect on cardiac function and kidney function, so as to treat sepsis more&#xD;
      effectively in the treatment of sepsis.&#xD;
&#xD;
      Recombinant human brain natriuretic peptide (rhBNP) was approved by FDA in 2001 for the&#xD;
      treatment of acute decompensated heart failure.These effects play a role in the protection of&#xD;
      cardiac and kidney function, and have achieved good results in patients with cardiac&#xD;
      insufficiency and AKI caused by cardiac surgery.&#xD;
&#xD;
      The investigators are going to carry out related research from the following aspects: 1. To&#xD;
      determine the effect of rhBNP on hemodynamics in sepsis based on PiCCO hemodynamic&#xD;
      monitoring; 2. To collect and sort out the relevant data to determine the effects of rhBNP on&#xD;
      cardiac function and kidney function, including cardiac ultrasound, kidney blood flow index&#xD;
      and related laboratory tests. 3. To determine the effect of rhBNP on the final prognosis of&#xD;
      patients, including ICU mortality and hospital mortality, ICU time, hospital stay, ventilator&#xD;
      use time, kidney replacement therapy time, vasoactive drug dosage and time.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the effects of rhBNP(recombinant human brain natriuretic peptide) on cardiac function</measure>
    <time_frame>72 hours after rhBNP</time_frame>
    <description>The decreasing trend of NTproBNP(N-terminal pro-B-type natriuretic peptide)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PiCCO hemodynamic monitoring in recombinant human brain natriuretic peptide group</measure>
    <time_frame>72 hours after recombinant human brain natriuretic peptide</time_frame>
    <description>The improvement degree of cardiac index in recombinant human brain natriuretic peptide group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ICU mortality and hospital mortality</measure>
    <time_frame>One month after entering ICU</time_frame>
    <description>Comparison between rhBNP group and control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanical ventilation time after entering ICU</measure>
    <time_frame>72 hours after recombinant human brain natriuretic peptide</time_frame>
    <description>Comparison between rhBNP group and control group</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>rhBNP in the treatment of sepsis complicated with heart failure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recombinant human brain natriuretic peptide (rhBNP) on sepsis complicated with heart failure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional treatment group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Do not use recombinant human brain natriuretic peptide (rhBNP) to treat sepsis with heart failure</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant human brain natriuretic peptide</intervention_name>
    <description>1. To determine the effect of rhBNP on hemodynamics in sepsis based on PiCCO hemodynamic monitoring; 2. To collect and sort out the relevant data to determine the effects of rhBNP on cardiac function and kidney function, including cardiac ultrasound, kidney blood flow index and related laboratory tests. 3. To determine the effect of rhBNP on the final prognosis of patients, including ICU mortality and hospital mortality, ICU time, hospital stay, ventilator use time, kidney replacement therapy time, vasoactive drug dosage and time.</description>
    <arm_group_label>rhBNP in the treatment of sepsis complicated with heart failure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  sepsis complicated with heart failure（Diagnosed by sepsis 3.0）&#xD;
&#xD;
          -  Heart failure: BNP rises by 600 pg/ml&#xD;
&#xD;
          -  Age&gt;=18 years old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hemodynamically unstable&#xD;
&#xD;
          -  Pregnant&#xD;
&#xD;
          -  Disagree with comprehensive and active life support treatment&#xD;
&#xD;
          -  coronary heart disease, myocardial infarction, and cardiac insufficiency&#xD;
&#xD;
          -  chronic renal insufficiency&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Minjie Ju, PHD</last_name>
    <phone>8613817014079</phone>
    <email>ju.minjie@zs-hospital.sh.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ju Minjie</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 30, 2021</study_first_submitted>
  <study_first_submitted_qc>October 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2021</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sepsis</keyword>
  <keyword>Heart Failure</keyword>
  <keyword>AKI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Natriuretic Peptide, Brain</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

